HumanexaHumanexaHumanexa
WelcomeSignalsCompaniesAssetsScenario AnalysisRegulatoryStrategy
InsightsNewslettersReportsBriefings
Pricing
WorkspaceTeamWatchlistsCollectionsSettings

Free

Intelligence Active

Regunera

FDA

Regulatory intelligence
FDAsafety guidance72% confidence

S9 Nonclinical Evaluation for Anticancer Pharmaceuticals--Questions and Answers

Source: FDA

Why This Matters

Why this matters: sets a safety guidance precedent in the same sub-indication (lung cancer) as Roche.

Regulatory Analysis

Supporting Context

Therapeutic area
Oncology · Small Cell Lung Cancer
Sub-indication
Lung Cancer

Related signal: RAPTOR Trial Evaluates Radiation Therapy with Atezolizumab in Extensive Stage Small Cell Lung Cancer

Source

View source document

Related Signal

Open signal — RAPTOR Trial Evaluates Radiation Therapy with Atezolizumab in Extensive Stage Small Cell Lung Cancer
PrivacyTermsRefund PolicyDisclaimerContact

© 2026 Humanexa. Intelligence for research workflows — not medical, legal, regulatory filing, or investment advice.